Needham & Company Upgrades ResMed (RMD) to Buy
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $231.52 +1.35%
Rating Summary:
11 Buy, 13 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
11 Buy, 13 Hold, 2 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Needham & Company analyst Mike Matson upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $180.00.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $153.89 yesterday.
You May Also Be Interested In
- Resmed Announces Appointment of Carol Burt as Lead Director and Planned Retirement of Director Ron Taylor
- ResMed names Carol Burt as lead director as Ron Taylor retires
- Freedom Broker Upgrades John B. Sanfilippo & Son, Inc. (JBSS) to Buy
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
